Global Parkinson's Disease Emerging Therapies Market - Strategic Insights and Forecasts (2026-2035)

The Global Parkinson's Disease Emerging Therapies Market is set to reach USD 1.63 billion in 2035, growing at a CAGR of 10.0% from USD 0.69 billion in 2026.

Parkinson’s disease remains one of the most prevalent neurodegenerative disorders worldwide and continues to create substantial clinical and societal burden. Existing therapies primarily focus on dopamine replacement and symptomatic management, which improve quality of life but do not prevent disease progression. This limitation is driving demand for therapies capable of modifying underlying biological mechanisms. Scientific advances are increasing the understanding of pathological processes associated with alpha-synuclein accumulation, mitochondrial dysfunction, neuroinflammation, and genetic risk factors. These developments are creating opportunities for innovative treatment approaches that address fundamental disease drivers.

The emerging therapies market encompasses investigational products across multiple modalities, including gene therapies, cell therapies, monoclonal antibodies, RNA-based treatments, and neuroprotective agents. Pharmaceutical companies are expanding investment in these areas because the unmet medical need remains substantial. Regulatory agencies are supporting development through scientific guidance and innovation-focused frameworks. The result is a rapidly evolving therapeutic ecosystem with the potential to reshape future Parkinson’s disease management.

Market Dynamics

Market Drivers

• Growing Focus on Disease Modification

Current therapies primarily manage symptoms without slowing neurodegeneration. This limitation is increasing the demand for disease-modifying interventions capable of altering disease progression. Pharmaceutical companies are expanding investment in novel biological targets. The outcome is accelerated clinical development activity across emerging therapeutic categories.

• Advances in Genetics and Biomarkers

Scientific understanding of Parkinson’s disease genetics continues to improve. Researchers are identifying patient populations associated with specific mutations and biological pathways. Biomarker programs are supporting more precise patient selection. The result is increasing adoption of targeted therapeutic development strategies.

• Rising Burden of Neurodegenerative Disease

Population ageing is increasing Parkinson’s disease prevalence globally. Healthcare systems are experiencing growing demand for long-term neurological care. Clinical researchers are prioritising therapies that may reduce future disability. The outcome is a stronger investment across the Parkinson’s disease innovation ecosystem.

• Expansion of Regenerative Medicine

Advances in stem cell technology and gene delivery systems are creating opportunities for restorative therapies. Developers are evaluating methods capable of replacing damaged neurons and improving neurological function. Clinical programs are expanding globally. The result is growing confidence in regenerative treatment approaches.

Market Restraints

• Long clinical development timelines increase investment risk and delay commercialisation.

• Absence of validated surrogate biomarkers complicates efficacy assessment during trials.

• Complex disease biology creates challenges in demonstrating disease-modifying benefit.

Market Opportunities

• Precision Medicine Development

Genetic and molecular profiling technologies are improving the understanding of disease heterogeneity. Targeted therapies are emerging for genetically defined patient populations. Clinical programs are becoming increasingly personalised. The outcome is greater therapeutic differentiation.

• Alpha-Synuclein Targeting Strategies

Alpha-synuclein pathology remains a central driver of disease progression. Multiple therapeutic platforms are targeting protein aggregation and propagation mechanisms. Research activity continues expanding. The result is a robust innovation environment focused on disease modification.

• Gene Therapy Innovation

Gene therapy technologies are improving delivery efficiency and long-term expression capabilities. Developers are evaluating approaches that restore dopamine production and protect neuronal survival. Clinical evidence continues to accumulate. The outcome is increasing commercial interest in advanced therapies.

• Neuroinflammation Modulation

Inflammatory processes contribute to neuronal injury and disease progression. Therapeutic programs targeting neuroinflammation are expanding. Clinical studies are investigating mechanisms capable of reducing chronic inflammatory responses. The result is a broader diversification of the development pipeline.

Disease Background and Unmet Needs

Parkinson’s disease is characterised by progressive degeneration of dopaminergic neurons within the substantia nigra and accumulation of alpha-synuclein pathology throughout the nervous system. Motor symptoms often emerge after significant neuronal loss has already occurred, limiting the effectiveness of late intervention strategies. Existing treatments improve symptom control but do not halt disease progression. Patients continue experiencing functional decline despite optimised therapy. This reality creates substantial demand for disease-modifying treatments capable of preserving neurological function and delaying disability.

Researchers are increasingly focusing on earlier intervention because biological damage begins years before clinical diagnosis. Biomarker identification efforts are supporting this objective by improving recognition of at-risk populations. The outcome is growing emphasis on preventive and disease-modifying therapeutic approaches.

Treatment Landscape

Market Segmentation

By Therapy Type

Disease-modifying therapies currently represent the most important emerging segment because healthcare providers and patients require interventions capable of slowing neurodegeneration. Alpha-synuclein-targeting therapies account for significant development activity as researchers seek to prevent pathological protein accumulation. Gene therapies are expanding due to their potential for durable biological effects, while cell therapies are attracting interest through regenerative medicine applications. LRRK2- and GBA-targeted therapies are supporting precision medicine approaches for genetically defined patient populations. Neuroinflammation and neuroprotective therapies continue to broaden the development landscape. The result is a diversified therapeutic ecosystem addressing multiple disease mechanisms.

By Molecule Type

Small molecules remain widely utilised because they offer favourable manufacturing, administration, and scalability characteristics. Monoclonal antibodies are gaining prominence as developers target extracellular pathological proteins and inflammatory pathways. Gene therapies are expanding through advances in viral vector technologies that support long-term therapeutic expression. Cell therapies are demonstrating potential to replace lost neuronal populations and restore neurological function. RNA-based therapies are emerging as attractive options for selective gene regulation. Peptide-based approaches continue to support targeted biological interventions. The outcome is increasing modality diversification across Parkinson’s disease clinical development programs.

By Route of Administration

Oral therapies remain attractive because they support long-term treatment adherence and patient convenience. Intravenous administration continues playing an important role for monoclonal antibodies and advanced biological therapies requiring systemic delivery. Subcutaneous approaches are gaining interest because they may improve treatment accessibility while reducing administration burden. Intrathecal delivery is becoming relevant for therapies targeting central nervous system structures directly. Intracerebral administration remains important for certain gene and cell therapy programs requiring precise localisation within affected brain regions. The result is ongoing innovation in delivery technologies supporting therapeutic effectiveness.

Regional Analysis

North America

North America represents the leading centre for Parkinson’s disease emerging therapy development because the region combines advanced neuroscience research infrastructure, strong biotechnology investment, and established regulatory pathways. Academic institutions, pharmaceutical companies, and biotechnology organisations are expanding research programs focused on disease modification, regenerative medicine, and precision neurology. Clinical trial activity remains concentrated in the United States because specialist movement disorder centres provide access to large patient populations and experienced investigators. Biomarker development initiatives are improving patient stratification and supporting more efficient clinical studies. The outcome is a highly active innovation ecosystem driving the advancement of next-generation Parkinson’s disease therapies.

The United States continues attracting significant venture capital and pharmaceutical investment because the unmet clinical need remains substantial. Gene therapy, cell therapy, and monoclonal antibody developers are establishing strategic partnerships to accelerate development timelines. Regulatory agencies are supporting innovation through programs designed for advanced therapies and serious neurological conditions. Canada is also contributing through academic research and participation in multinational clinical studies. The result is continued regional leadership in Parkinson’s disease therapeutic innovation.

Europe

Europe maintains a strong position in Parkinson’s disease emerging therapy development because the region possesses extensive neuroscience expertise, established academic networks, and supportive research funding frameworks. Pharmaceutical companies are expanding clinical programs targeting alpha-synuclein, neuroinflammation, lysosomal dysfunction, and genetic pathways associated with disease progression. Collaborative research initiatives are strengthening translational medicine efforts and improving movement from laboratory discovery to clinical development. The outcome is increasing diversification of investigational therapeutic approaches.

Countries including Germany, France, the United Kingdom, Switzerland, and Belgium continue supporting Parkinson’s disease innovation through academic-industry partnerships and specialised neurological research centres. Precision medicine programs are gaining importance as understanding of genetic risk factors improves. Regulatory harmonisation across European markets is facilitating multinational clinical studies and accelerating evidence generation. The result is a favourable environment for the development of advanced neurological therapies.

Asia Pacific

Asia Pacific is becoming increasingly important within the Parkinson’s disease emerging therapy landscape because healthcare investment, clinical research capacity, and biotechnology innovation continue expanding throughout the region. Japan remains a major contributor due to its ageing population, advanced neurological research capabilities, and strong pharmaceutical industry presence. Researchers are evaluating novel therapeutic approaches across disease-modifying, regenerative, and precision medicine categories. The outcome is growing regional participation in global clinical development programs.

China is expanding biotechnology investment and strengthening clinical trial infrastructure, which is increasing involvement in neurological research. South Korea and Australia continue contributing through advanced academic research and participation in multinational studies. Regional healthcare systems are improving awareness and diagnosis of Parkinson’s disease, creating larger patient pools for clinical investigation. The result is increasing strategic importance within the global development ecosystem.

Rest of the World

The Rest of the World region is gradually increasing participation in Parkinson’s disease research as healthcare infrastructure and neurological expertise continue improving. Latin American countries are contributing to multinational clinical studies because growing patient populations provide valuable research opportunities. Academic institutions are strengthening collaborations with international pharmaceutical companies and research organisations. The outcome is broader geographic diversification of clinical development activities.

Middle Eastern healthcare systems are expanding investment in specialised neurological services and research capabilities. Certain countries are establishing advanced medical centres capable of supporting participation in global clinical programs. African involvement remains limited compared with developed markets, although healthcare modernisation efforts are gradually improving neurological care access. The result is increasing global participation in Parkinson’s disease research and development initiatives.

Regulatory Landscape

Regulatory agencies are adapting frameworks to support the development of innovative Parkinson’s disease therapies because existing treatments do not adequately address disease progression. Advanced therapy medicinal products, gene therapies, and regenerative medicine platforms are receiving increased regulatory attention due to their potential to transform long-term disease outcomes. Developers are engaging with regulators earlier in the development process to align clinical trial design with evolving evidence requirements. The outcome is greater regulatory support for innovation in neurodegenerative disease treatment.

The U.S. Food and Drug Administration and European Medicines Agency are emphasising clinically meaningful endpoints that demonstrate functional improvement or disease modification. Biomarker integration is becoming increasingly important because earlier intervention strategies require more sensitive methods of measuring therapeutic impact. Developers are investing heavily in biomarker validation programs to support future regulatory submissions. The result is stronger alignment between scientific innovation and regulatory expectations.

Gene therapies and cell therapies face additional regulatory scrutiny because of their complexity and long-term safety considerations. Agencies are requiring comprehensive manufacturing controls, durability assessments, and post-treatment monitoring programs. Developers are strengthening quality systems and clinical evidence generation efforts to address these requirements. The outcome is a robust regulatory environment balancing innovation with patient safety.

Pipeline Analysis

The Parkinson’s disease pipeline is becoming increasingly diverse as developers pursue multiple biological mechanisms associated with disease progression. Alpha-synuclein-targeting therapies remain among the largest categories because pathological protein aggregation plays a central role in disease pathology. Monoclonal antibodies, small molecules, and RNA-based approaches are being evaluated for their ability to reduce protein accumulation and limit neuronal injury. The result is continued expansion of disease-modifying therapeutic strategies.

Gene therapy development is accelerating because advances in vector engineering are improving delivery efficiency and therapeutic durability. Companies including AskBio and Voyager Therapeutics are investigating approaches designed to restore dopaminergic function or modify disease-related pathways. Researchers are also exploring therapies targeting GBA and LRRK2 mutations, reflecting growing interest in precision medicine. The outcome is increasing specialisation within the development landscape.

Cell therapy programs are demonstrating significant promise because stem-cell-derived dopaminergic neurons may replace cells lost during disease progression. BlueRock Therapeutics and other regenerative medicine developers are advancing clinical programs evaluating neuronal replacement strategies. Positive long-term outcomes could substantially alter future treatment paradigms. The result is growing interest in regenerative approaches capable of addressing underlying neurological damage.

Neuroinflammation, mitochondrial dysfunction, lysosomal impairment, and protein clearance mechanisms continue attracting research investment because Parkinson’s disease involves multiple interconnected biological processes. Companies are increasingly combining genetic, biomarker, and imaging technologies to improve patient selection and therapeutic evaluation. The outcome is a sophisticated pipeline targeting diverse disease mechanisms through personalised treatment strategies.

Reimbursement Landscape

Reimbursement systems currently focus on symptomatic therapies because disease-modifying Parkinson’s disease treatments have not yet achieved widespread commercialisation. Healthcare payers are closely monitoring emerging clinical data because future therapies may significantly alter long-term disease burden and healthcare utilisation patterns. The outcome is growing interest in evaluating the economic impact of innovative interventions.

Gene therapies and cell therapies are expected to require specialised reimbursement frameworks because development and manufacturing costs are substantially higher than conventional pharmacological treatments. Payers are exploring outcomes-based reimbursement models that link payment to long-term clinical benefit. Pharmaceutical companies are preparing health economic evidence packages to demonstrate value beyond symptom management. The result is increasing discussion around innovative reimbursement structures.

As disease-modifying therapies advance toward commercialisation, reimbursement decisions will likely depend on demonstrated ability to slow disease progression, reduce disability, and decrease long-term healthcare costs. Biomarker-guided treatment approaches may further support value-based reimbursement by improving patient selection. The outcome is a reimbursement environment increasingly focused on measurable clinical outcomes and healthcare system sustainability.

Competitive Landscape

AbbVie Inc.

AbbVie maintains a significant presence in neuroscience and movement disorders through investments in advanced neurological therapeutics and strategic research collaborations. The company is expanding its Parkinson’s disease emerging therapy portfolio by evaluating novel mechanisms that address unmet needs beyond symptomatic control. Research activities focus on improving long-term patient outcomes through therapies capable of modifying disease progression and reducing neurological decline. AbbVie benefits from extensive global commercialisation infrastructure and neuroscience expertise, which support rapid development and future market access opportunities. Continued investment in neurodegenerative disease innovation strengthens the company’s competitive position within the Parkinson’s disease emerging therapies landscape.

Roche Holding AG

Roche differentiates itself through extensive expertise in neuroscience, biomarker development, precision medicine, and advanced diagnostics. The company is actively pursuing Parkinson’s disease programs targeting alpha-synuclein pathology and disease-modifying mechanisms. Integrated diagnostic capabilities support the identification of appropriate patient populations and improve clinical trial efficiency. Roche continues expanding collaborations with academic institutions and biotechnology organisations to accelerate innovation. Its strong research infrastructure and global development network provide significant advantages in advancing next-generation therapies. The company remains strategically positioned to play a major role in future Parkinson’s disease treatment transformation.

Denali Therapeutics Inc.

Denali Therapeutics focuses exclusively on neurodegenerative diseases and has developed a specialised platform targeting biological mechanisms associated with disease progression. The company is advancing therapies addressing lysosomal dysfunction, neuroinflammation, and neuronal degeneration pathways implicated in Parkinson’s disease. Scientific innovation remains central to its development strategy, with programs designed to alter disease biology rather than simply manage symptoms. Strategic partnerships and advanced translational research capabilities strengthen clinical development efforts. Denali’s focused approach positions the company as one of the leading innovators within the Parkinson’s disease emerging therapy ecosystem.

Biogen Inc.

Biogen leverages extensive neuroscience expertise and experience in neurodegenerative disease development to pursue innovative Parkinson’s disease therapies. The company is evaluating multiple approaches aimed at modifying disease progression and improving long-term neurological outcomes. Research initiatives focus on addressing key biological pathways involved in neurodegeneration and functional decline. Biogen’s established capabilities in clinical development, regulatory engagement, and global commercialisation provide substantial competitive advantages. Continued investment in neurological innovation supports the expansion of its emerging therapy portfolio and reinforces its strategic importance within the evolving Parkinson’s disease landscape.

UCB S.A.

UCB maintains a strong neuroscience focus and continues investing in therapies targeting complex neurological disorders. Parkinson’s disease represents an important area of strategic interest because unmet clinical needs remain substantial despite advances in symptomatic treatment. The company is evaluating novel therapeutic approaches designed to improve patient outcomes and address disease progression mechanisms. Global development capabilities and strong physician relationships support future commercialisation opportunities. UCB’s commitment to patient-centred innovation and neuroscience research positions the company as an important contributor to the Parkinson’s disease emerging therapies market.

Bayer AG

Bayer is expanding its presence in neurodegenerative disease research through investments in precision medicine, cell therapy, and regenerative medicine technologies. The company is exploring innovative approaches that may provide disease-modifying benefits for Parkinson’s disease patients. Strategic partnerships and acquisitions have strengthened Bayer’s access to advanced neurological research capabilities. Scientific efforts focus on restoring neuronal function and improving long-term disease outcomes. The company’s global scale, research resources, and commitment to innovation support continued participation in the rapidly evolving Parkinson’s disease therapeutic landscape.

BlueRock Therapeutics LP

BlueRock Therapeutics is a leading developer of regenerative medicine solutions and is recognised for pioneering stem-cell-based approaches targeting neurological diseases. The company’s Parkinson’s disease programs focus on replacing damaged dopaminergic neurons through advanced cell therapy technologies. Research efforts aim to restore lost neurological function rather than simply compensate for symptoms. Strong scientific expertise in cellular engineering and regenerative medicine supports differentiated clinical development strategies. BlueRock’s innovative platform positions the company at the forefront of cell therapy development for Parkinson’s disease.

AskBio Inc.

AskBio specialises in gene therapy development and utilises adeno-associated viral vector technologies to address neurological disorders. The company is advancing Parkinson’s disease programs designed to enhance neuronal function and improve dopamine-related signalling pathways. Scientific efforts focus on achieving durable therapeutic benefit through long-term gene expression. Strategic support from larger biotechnology and pharmaceutical partners strengthens development capabilities and accelerates clinical progress. AskBio’s expertise in gene delivery technologies provides a strong foundation for future advancement within the Parkinson’s disease emerging therapy market.

Voyager Therapeutics, Inc.

Voyager Therapeutics focuses on next-generation gene therapy platforms targeting diseases of the central nervous system. The company is leveraging proprietary vector technologies to improve delivery efficiency and therapeutic performance. Parkinson’s disease development programs are designed to address underlying biological dysfunction through targeted genetic intervention. Research investments continue supporting the expansion of its neurological pipeline. Strategic collaborations enhance access to development resources and scientific expertise. Voyager’s emphasis on innovative gene therapy technologies supports a differentiated competitive position within the emerging Parkinson’s disease treatment landscape.

Neurocrine Biosciences, Inc.

Neurocrine Biosciences has established significant expertise in neurological and movement disorders through the development of therapies addressing complex central nervous system conditions. The company is expanding research efforts targeting Parkinson’s disease and related movement disorders. Clinical development activities focus on improving symptom control while exploring opportunities to influence underlying disease mechanisms. Strong neuroscience capabilities and commercial experience support future growth within the Parkinson’s disease segment. Continued investment in neurological innovation enhances Neurocrine’s strategic relevance in the emerging therapy market.

Acadia Pharmaceuticals Inc.

Acadia Pharmaceuticals specialises in central nervous system disorders and maintains strong expertise in neurological disease management. The company is evaluating emerging opportunities within Parkinson’s disease through programs addressing both motor and non-motor disease manifestations. Research efforts are focused on improving the quality of life and reducing the disease burden among affected patients. Strong relationships within the neurology community support clinical development initiatives and future commercialisation potential. Acadia’s specialised focus on CNS disorders strengthens its ability to participate in the evolving Parkinson’s disease treatment landscape.

Eli Lilly and Company

Eli Lilly is increasing investment in neurodegenerative disease research as advances in neuroscience create opportunities for innovative therapeutic development. The company is exploring Parkinson’s disease programs targeting disease-modifying mechanisms and neuroprotective pathways. Extensive research capabilities, global clinical infrastructure, and significant financial resources support long-term development efforts. Lilly’s experience in biologics, precision medicine, and complex disease management enhances its ability to pursue differentiated treatment strategies. Continued expansion within neuroscience positions the company as a potentially important future participant in Parkinson’s disease innovation.

Gain Therapeutics, Inc.

Gain Therapeutics focuses on allosteric small-molecule therapies targeting protein misfolding and lysosomal dysfunction. The company is advancing programs designed to address GBA-related Parkinson’s disease through restoration of normal enzyme function and cellular homeostasis. Scientific efforts concentrate on correcting underlying biological abnormalities associated with disease progression. Precision medicine approaches remain central to the company’s strategy. Growing interest in genetically targeted therapies supports the increasing relevance of Gain’s development programs. The company occupies a specialised niche within the broader Parkinson’s disease emerging therapies ecosystem.

Bial - Portela & Cª, S.A.

Bial has developed extensive expertise in neurology and movement disorders through years of focused research and product development. The company continues evaluating innovative approaches designed to improve treatment outcomes for Parkinson’s disease patients. Research programs emphasise both symptomatic improvement and exploration of future disease-modifying opportunities. International expansion efforts are strengthening access to broader patient populations and research networks. Bial’s specialised neurological focus and commitment to scientific advancement support continued participation in the evolving Parkinson’s disease therapeutic landscape.

Novartis AG

Novartis remains one of the world’s leading pharmaceutical innovators and continues investing in advanced neurological research. The company is exploring opportunities across gene therapy, precision medicine, and disease-modifying therapeutic platforms relevant to Parkinson’s disease. Strong expertise in biologics, cell and gene therapies, and translational medicine supports the development of innovative treatment strategies. Global clinical infrastructure and regulatory experience provide substantial competitive advantages. Continued focus on high-value neurological innovation positions Novartis as a significant participant in the future evolution of Parkinson’s disease emerging therapies.

Key Developments

• May 2025: Roche Holding AG announced continued advancement of its alpha-synuclein-targeting Parkinson’s disease research programs, reinforcing its focus on disease-modifying therapies aimed at slowing neurodegeneration rather than providing symptomatic relief.

• April 2025: Denali Therapeutics Inc. reported progress in clinical studies evaluating lysosomal pathway-targeting therapies for Parkinson’s disease, supporting the development of treatments designed to address underlying disease biology.

• March 2025: AbbVie Inc. expanded neuroscience research collaborations focused on neurodegenerative diseases, including Parkinson’s disease, to accelerate the development of novel therapeutic candidates and biomarker-driven approaches.

• February 2025: BlueRock Therapeutics LP continued clinical evaluation of stem-cell-based regenerative therapies designed to replace dopaminergic neurons lost in Parkinson’s disease, representing a significant advancement in restorative treatment strategies.

Strategic Insights and Future Market Outlook

The Parkinson’s disease emerging therapies landscape is undergoing a fundamental transition from symptomatic management toward disease-modifying intervention. Scientific understanding of alpha-synuclein aggregation, lysosomal dysfunction, neuroinflammation, mitochondrial impairment, and genetic mutations is expanding, which is driving investment into therapies that target underlying disease biology rather than motor symptom control alone. Developers are increasingly focusing on earlier disease stages because intervention before extensive neuronal loss may provide greater clinical benefit. This shift is increasing demand for biomarkers, patient stratification tools, and precision medicine approaches capable of identifying appropriate treatment populations.

Gene therapy and cell therapy platforms are emerging as major innovation areas because conventional pharmacological approaches have demonstrated limited ability to slow neurodegeneration. Companies are advancing viral vector-based gene therapies designed to restore dopamine production, enhance neuronal survival, or modify disease-causing pathways. Cell replacement strategies utilising stem-cell-derived dopaminergic neurons are progressing through clinical development, reflecting growing confidence in regenerative medicine applications for neurodegenerative disorders. The result is a diversified development pipeline addressing multiple mechanisms of disease progression simultaneously.

Genetically targeted therapies are becoming increasingly important as researchers identify patient subgroups associated with LRRK2 and GBA mutations. Precision medicine programs are improving patient selection and increasing the probability of demonstrating meaningful clinical outcomes. Pharmaceutical companies are establishing partnerships with genetic testing providers and biomarker developers to support these targeted approaches. This evolution is creating opportunities for differentiated therapies capable of serving well-defined patient populations while potentially improving therapeutic effectiveness.

Alpha-synuclein-targeting therapies remain a central focus because pathological protein aggregation is considered one of the most important drivers of Parkinson’s disease progression. Monoclonal antibodies, small molecules, and RNA-based approaches are being evaluated across multiple clinical programs. At the same time, neuroinflammation-targeting therapies are gaining momentum because chronic inflammatory responses contribute to neuronal injury and disease advancement. The convergence of these approaches is expanding the range of investigational treatment options available within the clinical pipeline.

By 2035, the Parkinson’s disease treatment paradigm is expected to become increasingly personalised, with biomarker-guided therapeutic selection, earlier intervention strategies, and broader adoption of disease-modifying treatments. Companies that successfully demonstrate clinical efficacy in slowing disease progression while maintaining favourable safety profiles are likely to establish leadership positions within the future therapeutic landscape. Continued advances in genetics, biomarker science, neuroimaging, and regenerative medicine will shape the next generation of Parkinson’s disease therapies and significantly influence long-term patient outcomes.

Global Parkinson's Disease Emerging Therapies Market Scope: